๐ฐ Comparative Effectiveness News
Page 2 - Comparative Effectiveness News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Comparative Effectiveness. Real-time updates on events, politics, business and more.
September 18, 2023
Type 2 diabetes is a chronic and progressive cardiometabolic disorder that affects more than 10% of adults worldwide and is a major cause of morbidity, mortality, disability, and high costs. Over the past decade, the pattern of management of diabetes has shifted from a predominantly glucose centric approach, focused on lowering levels of haemoglobin A1c (HbA1c), to a directed complications centric approach, aimed at preventing short term and long term complications of diabetes, and a pathogenesi...
September 9, 2023
Not all of drug innovations are created equal. Some arenโt better than existing standards of care. Others are breakthroughs. Still others are marginal improvements.
August 4, 2023
BURLINGTON, Mass., August 04, 2023--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-...
August 4, 2023
Analysis published in the Journal of Comparative Effectiveness Research shows ropeginterferon alfa-2b-njft provided a cost-effective benefit in quality-adjusted life years compared to a commonly used treatment pathwayBURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia C...
June 27, 2023
In depth information about various types of external beam radiotherapy for treatment of prostate cancer. Radiotherapy is an alternative to surgical treatment such as radical prostatectomy.
May 30, 2023
1. In this retrospective cohort study, glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of major adverse cardiac events (MACE) in veterans with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors (DPP4i). 2. The addition of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) was not associated with a primary reduction in major adverse cardiac
May 26, 2023
Researchers evaluated the kidney outcomes in individuals with type 2 diabetes.
May 24, 2023
Unipolar depression, or major depressive disorder, is a mental health condition. Learn about the symptoms, causes, and treatments here 2023.
May 24, 2023
Unipolar depression, or major depressive disorder, is a mental health condition. Learn about the symptoms, causes, and treatments here 2023.
May 24, 2023
Unipolar depression, or major depressive disorder, is a mental health condition. Learn about the symptoms, causes, and treatments here 2023.